Hepatitis C virus (HCV) was first identified in 1981. It has affected nearly 200 million
people worldwide. The current treatment regimen has severe side effects and it demands new and effective
drugs. In drug design and development, QSAR (Quantitative Structure-Activity Relationship) studies are of
great help as they rationalize the drug synthesis and explain drug-receptor interactions. We performed a
QSAR analysis on a data set of 33 acridone derivatives acting as HCV RNA replication inhibitors. The
obtained correction has shown significant contribution of calculated molar refractivity, and hydrophobicity
with rcv
2 = 0.87. These results can be used to design novel scaffolds acting as anti-HCV agents.